News articles about Metlife (NYSE:MET) have been trending somewhat positive recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Metlife earned a media sentiment score of 0.83 on their scale. InfoTrie also assigned news stories about the financial services provider an news buzz score of 10 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company’s share price in the next few days.

These are some of the news articles that may have effected Metlife’s analysis:

Several brokerages recently weighed in on MET. Zacks Investment Research upgraded shares of Metlife from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a report on Friday, October 5th. UBS Group increased their price target on shares of Metlife from $48.00 to $49.00 and gave the stock a “neutral” rating in a report on Monday, October 8th. Wells Fargo & Co reiterated a “buy” rating and issued a $60.00 price target on shares of Metlife in a report on Thursday, September 27th. Sandler O’Neill reiterated a “hold” rating and issued a $50.00 price target on shares of Metlife in a report on Thursday, August 2nd. Finally, Credit Suisse Group cut their price target on shares of Metlife from $67.00 to $63.00 and set an “outperform” rating on the stock in a report on Friday, August 17th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company’s stock. Metlife presently has a consensus rating of “Hold” and a consensus target price of $53.92.

Shares of NYSE:MET opened at $42.84 on Wednesday. Metlife has a twelve month low of $39.31 and a twelve month high of $55.21. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.14 and a current ratio of 0.14. The company has a market capitalization of $43.38 billion, a P/E ratio of 9.52, a price-to-earnings-growth ratio of 0.66 and a beta of 1.30.

Metlife (NYSE:MET) last released its quarterly earnings data on Thursday, November 1st. The financial services provider reported $1.38 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.27 by $0.11. Metlife had a return on equity of 9.76% and a net margin of 7.62%. The business had revenue of $16.40 billion for the quarter, compared to analyst estimates of $15.88 billion. During the same quarter in the prior year, the firm posted $1.09 EPS. The business’s quarterly revenue was down 2.2% compared to the same quarter last year. On average, analysts forecast that Metlife will post 5.33 earnings per share for the current year.

Metlife announced that its board has approved a stock buyback program on Thursday, November 1st that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the financial services provider to reacquire up to 4.6% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its stock is undervalued.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 13th. Shareholders of record on Tuesday, November 6th will be given a $0.42 dividend. The ex-dividend date is Monday, November 5th. This represents a $1.68 annualized dividend and a yield of 3.92%. Metlife’s dividend payout ratio is presently 37.33%.

In other Metlife news, Chairman Steven A. Kandarian sold 42,805 shares of the company’s stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $47.03, for a total value of $2,013,119.15. Following the sale, the chairman now owns 559,097 shares in the company, valued at approximately $26,294,331.91. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.34% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was published by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at

About Metlife

MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.

See Also: Asset Allocation Models, Which is Right For You?

Insider Buying and Selling by Quarter for Metlife (NYSE:MET)

Receive News & Ratings for Metlife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife and related companies with's FREE daily email newsletter.